Prof. Xie Fangyun was born in 1962. He completed his master's program from the former Sun Yat-sen University of Medical Sciences, and has been engaged in medical treatment, teaching and scientific research at Sun Yat-sen University Cancer Center for more than 38 years. 

Prof. Xie specializes in radiotherapy for head and neck cancer, especially the optimization researches of TNM staging system, comprehensive treatment and prognosis prediction for nasopharyngeal carcinoma (NPC). He has been the Principal or Co-Principal Investigator of several major projects funded by National Natural Science Foundation of China and Ministry of Health, Sun Yat-sen University 5010 Clinical Research Program. 

As the first author or corresponding author, Prof. Xie has published over 50 papers in leading, international peer-reviewed journals of oncology such as Lancet, New Engl J Med, BMJ, Annals of Oncology, Lancet Oncol, J Clin Oncol, EClinicalMedicine, Int J Radiat Oncol Biol Phys and J Transl Med on staging system, prognosis models, comprehensive treatment and etc. of NPC. He has received the “Chinese Medical Science and Technology Award” (2007), “National Science and Technology Progress Award” (2009), “Guangdong Province Dingying Science & Technology Progress Award” (2009), “Higher Education Science and Technology Progress Award” (2020), “Guangdong Medical Science and Technology Award” (2020), “Guangdong Province Science and Technology Progress Award” (2021).

Optimization researches of TNM staging system, comprehensive treatment and prognosis prediction for NPC. Design and conduct of phase II and III clinical trials in the field of NPC. Preclinical basic researches focusing on radiosensitivity and signal pathways related with the development of NPC.

09/1990-07/1994 Master’s degree of Oncology, Sun Yat-sen University of Medical Sciences, Guangzhou, China

07/1980-09/1985 Bachelor of Medicine, Hu Nan Medical College, Changsha, China

1.Chen YP#, Liu X#, Zhou Q#, Yang KY#, Jin F#, Zhu XD#, Shi M#, Hu GQ#, Hu WH#, Sun Y, Wu HF, Wu H, Lin Q, Wang H, Tian Y, Zhang N, Wang XC, Shen LF, Liu ZZ, Huang J, Luo XL, Li L, Zang J, Mei Q, Zheng BM, Yue D, Xu J, Wu SG, Shi YX, Mao YP, Chen L, Li WF, Zhou GQ, Sun R, Guo R, Zhang Y, Xu C, Lv JW, Guo Y, Feng HX, Tang LL*, Xie FY*, Sun Y*, Ma J*. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2021 Jun 4:S0140-6736(21)01123-5.(IF 168.9)

2. Zhang Y#, Chen L#, Hu GQ#, Zhang N#, Zhu XD#, Yang KY#, Jin F#, Shi M#, Chen YP#, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Tang LL, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Chua MLK*, Xie FY*, Sun Y*, Ma J*. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med. 2019 Sep 19;381(12):1124-1135.  (IF 158.5)

3.Mao YP#, Wang SX#, Gao TS#, Zhang N#, Liang XY#, Xie FY#, Zhang Y, Zhou GQ, Guo R, Luo WJ, Li YJ, Liang SQ, Lin L, Li WF, Liu X, Xu C, Chen YP, Lv JW, Huang SH, Liu LZ, Li JB, Tang LL, Chen L, Sun Y, Ma J*. Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial. BMJ. 2023 Feb 6;380:e072133. (IF 105.7)

4.Sun Y#, Li WF#, Chen NY#, Zhang N#, Hu GQ#, Xie FY#, Sun Y#, Chen XZ, Li JG, Zhu XD, Hu CS, Xu XY, Chen YY, Hu WH, Guo L, Mo HY, Chen L, Mao YP, Sun R, Ai P, Liang SB, Long GX, Zheng BM, Feng XL, Gong XC, Li L, Shen CY, Xu JY, Guo Y, Chen YM, Zhang F, Lin L, Tang LL, Liu MZ, Ma J*. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016 Nov;17(11):1509-1520. (IF 51.1)

5. OuYang PY#, Xie C#, Mao YP, Zhang Y, Liang XX, Su Z, Liu Q, Xie FY*. Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis of published literature-based randomized, controlled trials. Ann Oncol. 2013 Aug;24(8):2136-46. (IF 50.5)

6.Zhang Y#, Chen L#, Hu GQ#, Zhang N#, Zhu XD#, Yang KY#, Jin F#, Shi M#, Chen YP#, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Xie FY*, Sun Y*, Ma J*, Tang LL*. Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial. J Clin Oncol. 2022 Jun 16:JCO2200327. (IF 45.3)

7.OuYang PY#, You KY#, Zhang LN#, Xiao Y, Zhang XM, Xie FY*. External validity of a prognostic nomogram for locoregionally advanced nasopharyngeal carcinoma based on the 8th edition of the AJCC/UICC staging system: a retrospective cohort study. Cancer Commun (Lond). 2018 Sep 3;38(1):55. (IF 16.2)

8.OuYang PY#, Zhang BY#, Guo JG#, Liu JN#, Li J, Peng QH, Yang SS, He Y, Liu ZQ, Zhao YN, Li A, Wu YS, Hu XF, Chen C, Han F*, You KY*, Xie FY*. Deep learning-based precise prediction and early detection of radiation-induced temporal lobe injury for nasopharyngeal carcinoma. EClinicalMedicine. 2023 Apr 4;58:101930. (IF 15.1)

9.OuYang PY#, Liu ZQ#, Lin QG#, He Y#, Guo ZX, Yao WY, Xu SK, Peng QH, Xiao SM, Li J, Li A, Zhang BY, Yang SS, Fan W, Xie CM, Wu YS*, Zhang X*, Chen CY*, Xie FY*. Benefit of [18F] FDG PET/CT in the diagnosis and salvage treatment of recurrent nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2023 Feb;50(3):881-891. (IF 9.1)

10.Yang SS#, Wu YS#, Chen WC#, Zhang J, Xiao SM, Zhang BY, Liu ZQ, Chen EN, Zhang X*, OuYang PY*, Xie FY*. Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):980-991. (IF 9.1)

11. Chen E#, Huang J#, Chen M#, Wu J, Ouyang P, Wang X, Shi D, Liu Z, Zhu W, Sun H, Yang S, Zhang B, Deng W*, Qiu H*, Xie F*. FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway. J Transl Med. 2023 Feb 22;21(1):134. (IF 7.4)

12.Yang SS#, OuYang PY#, Guo JG#, Cai JJ#, Zhang J, Peng QH, He Y, Zhang BY, Liu ZQ, Hu XF, Chen YF, Chen CY*, Xie FY*. Dosiomics Risk Model for Predicting Radiation Induced Temporal Lobe Injury and Guiding Individual Intensity-Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2023 Apr 1;115(5):1291-1300. (IF 7.0)

Updated by International Office, Sun Yat-sen University Cancer Center